Loading...
•
Sep 30, 2021
United Therapeutics Q3 2021 Earnings Report
United Therapeutics reported a revenue increase driven by growing patient use of medicines and progress in clinical trials.
Key Takeaways
United Therapeutics Corporation announced its Q3 2021 financial results, with total revenue growing 17% year over year to $444.7 million. The company is progressing with six phase 3 clinical trials across various forms of pulmonary hypertension and pulmonary fibrosis and continues to add new Tyvaso patients, reaching approximately 4,000 U.S. patients on Tyvaso therapy at the end of the third quarter.
Total revenue increased by 17% year-over-year, reaching $444.7 million.
Net income was $162.7 million, compared to $171.2 million in the third quarter of 2020.
Non-GAAP earnings were $198.0 million, a 14% increase compared to $173.0 million in the third quarter of 2020.
Approximately 4,000 U.S. patients on Tyvaso therapy at the end of the third quarter.
United Therapeutics
United Therapeutics
United Therapeutics Revenue by Segment
Revenue by Segment
Tyvaso Revenue
CapyFin.comRemodulin Revenue
CapyFin.comOrenitram Revenue
CapyFin.comUnituxin Revenue
CapyFin.comAdcirca Revenue
CapyFin.com Forward Guidance
The company provided forward-looking statements regarding revenue growth prospects, the goal of reaching 6,000 U.S. patients on Tyvaso by the end of 2022, expectations concerning the timing and success of efforts to obtain the necessary FDA approvals to launch Tyvaso DPI, research and development plans related to the PERFECT and TETON studies of Tyvaso, and the ADVANCE studies of ralinepag.
Positive Outlook
- Revenue growth prospects
- Goal of reaching 6,000 U.S. patients on Tyvaso by the end of 2022
- Expectations concerning the timing and success of efforts to obtain the necessary FDA approvals to launch Tyvaso DPI
- Research and development plans related to the PERFECT and TETON studies of Tyvaso
- The ADVANCE studies of ralinepag
Challenges Ahead
- Risk that we will not obtain the necessary FDA approvals to launch Tyvaso DPI
- Uncertainties related to clinical trial outcomes
- Dependence on regulatory approvals
- Competition in the market
- General economic conditions
Revenue & Expenses
Visualization of income flow from segment revenue to net income